Summary

Androgenetic Alopecia Market Growth & Trends

The global androgenetic alopecia market size is anticipated to reach USD 4.76 billion by 2030 and is anticipated to expand at a CAGR of 8.45% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of androgenetic alopecia is one of the crucial factors driving the market growth. According to data published by the American Hair Loss Association, over 95% of hair loss in men is caused due to androgenetic alopecia. The occurrence of hair loss in men increases proportionately with age. On the basis of the report published by the International Society of Hair Restoration Surgery, in men, it is estimated that 40% of hair loss is encountered by the age of 35 years, 65% at 60 years, 70% at 80 years, and 80% at the age of 85 years.

Moreover, the market growth can be attributed to advancements in technology, including the introduction of a low-level laser therapy, which helps stimulate hair growth. Likewise, the introduction of several laser combs and hair massagers or brushes is also boosting the market. For instance, Lifemax Infrared Hairbrush, Follinex Massager Comb, and Hairmax Laser Comb are some of the technologically advanced products available in the market. Most clinical-based settings offer combination therapy of non-ablative laser treatment and topical application of medicinal products for better results. Microscopic injuries created by laser devices create a favorable wound-healing environment that triggers hair regrowth.

Furthermore, the increasing incidence of chronic diseases such as cancer is anticipated to offer lucrative opportunities for market growth. For instance, according to the latest report by Globocan, the incidence of cancer was estimated to be 19,288,916 in 2020 globally. Certain medications prescribed to patients for the treatment of cancer are also responsible for hair loss. For instance, chemotherapeutic agents, radiation therapy, hormone therapy, and immunotherapy are more likely to induce hair loss or hair thinning. Cancer incidence is expected to rise by about 70% over the next two decades, thus driving the market growth.

However, reimbursement coverage for androgenetic alopecia treatment is one of the major challenges in this market. Since most treatment modalities for AGA are considered cosmetic procedures and not medically essential ones, they are generally not covered under insurance. Out-of-pocket costs for AGA treatment usually include frequent doctor visits, prescription drug copays, and coinsurance for procedures. Alopecia has complex reimbursement positioning, as it is not a life-threatening disease. For instance, Aetna Inc.’s policy for alopecia states that drugs covered for mild conditions are different from those considered for more severe conditions. In addition, the scheme does not cover Rogaine (minoxidil) as it is considered an experimental therapy. Thus, lack of reimbursement policies for treatment is restraining the market growth.

Androgenetic Alopecia Market Report Highlights

• The male segment dominated the market in 2023 due to the high adoption of androgenetic alopecia treatments

• The pharmaceuticals segment held the largest share in 2023. The increasing number of product approvals, rising investments by pharmaceutical companies, and shift in societal attitude toward adopting pharmaceutical drugs for the treatment of androgenetic alopecia are likely to play a prominent role in segment growth

• The devices treatment segment is expected to grow at the fastest CAGR over the forecast period

• The dermatology clinics end-use segment accounted for the largest revenue share in 2023 owing to increased consumer awareness regarding prescription medicines & modern treatments, such as laser technology, coupled with a strong product pipeline

• North America held a dominant revenue share in 2023 due to the high disease prevalence, consumer awareness, proactive government measures, technological advancements, and improvements in healthcare infrastructure

• In November 2023, Sun Pharma Advanced Research Company (SPARC) entered into an agreement with Johns Hopkins and the Czech research institute IOCB to exclusively license SCD-153, including all patents owned by IOCB

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Gender
1.2.2. Treatment
1.2.3. End Use
1.2.4. Sales Channel
1.2.5. Regional scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in Asia Pacific
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Gender outlook
2.2.2. Treatment outlook
2.2.3. End use outlook
2.2.4. Sales channel outlook
2.2.5. Regional outlook
2.3. Competitive Insights
Chapter 3. Androgenetic Alopecia Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of androgenic alopecia
3.2.1.2. Technological advancements in androgenic alopecia
3.2.2. Market restraint analysis
3.2.2.1. Lack of reimbursement policies for androgenic alopecia
3.2.3. Market opportunity analysis
3.2.3.1. Increasing prevalence of chronic diseases
3.3. Androgenetic Alopecia Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.4. Androgenetic Alopecia Market: Prevalence Data, By Region
3.4.1. North America
3.4.1.1. U.S.
3.4.1.2. Canada
3.4.2. Europe
3.4.2.1. UK
3.4.2.2. Germany
3.4.2.3. France
3.4.2.4. Italy
3.4.2.5. Spain
3.4.2.6. Denmark
3.4.2.7. Sweden
3.4.2.8. Norway
3.4.3. Asia Pacific
3.4.3.1. Japan
3.4.3.2. China
3.4.3.3. India
3.4.3.4. South Korea
3.4.3.5. Australia
3.4.3.6. Thailand
3.4.4. Latin America
3.4.4.1. Brazil
3.4.4.2. Mexico
3.4.4.3. Argentina
3.4.5. Middle East and Africa (MEA)
3.4.5.1. South Africa
3.4.5.2. Saudi Arabia
3.4.5.3. UAE
3.4.5.4. Kuwait
Chapter 4. Androgenetic Alopecia Market: Gender Estimates & Trend Analysis
4.1. Gender Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Androgenetic Alopecia Market by Gender Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Male
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Female
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Androgenetic Alopecia Market: Treatment Estimates & Trend Analysis
5.1. Treatment Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Androgenetic Alopecia Market by Treatment Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Pharmaceuticals
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Devices
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Androgenetic Alopecia Market: End-use Estimates & Trend Analysis
6.1. End-use Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Global Androgenetic Alopecia Market by End Use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Dermatology Clinics
6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
6.4.2. Homecare Settings
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Androgenetic Alopecia Market: Sales Channel Estimates & Trend Analysis
7.1. Sales Channel Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. Global Androgenetic Alopecia Market by Sales Channel Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.4.1. Prescription
7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. OTC
7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Androgenetic Alopecia Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2023 & 2030
8.2. Regional Market Dashboard
8.3. Global Regional Market Snapshot
8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.5. North America
8.5.1. U.S.
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework/ reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.5.2. Canada
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework/ reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.6. Europe
8.6.1. UK
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/ reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.6.2. Germany
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.6.3. France
8.6.3.1. Key country dynamics
8.6.3.2. Regulatory framework/ reimbursement structure
8.6.3.3. Competitive scenario
8.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.6.4. Italy
8.6.4.1. Key country dynamics
8.6.4.2. Regulatory framework/ reimbursement structure
8.6.4.3. Competitive scenario
8.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.6.5. Spain
8.6.5.1. Key country dynamics
8.6.5.2. Regulatory framework/ reimbursement structure
8.6.5.3. Competitive scenario
8.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.6.6. Norway
8.6.6.1. Key country dynamics
8.6.6.2. Regulatory framework/ reimbursement structure
8.6.6.3. Competitive scenario
8.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.6.7. Sweden
8.6.7.1. Key country dynamics
8.6.7.2. Regulatory framework/ reimbursement structure
8.6.7.3. Competitive scenario
8.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.6.8. Denmark
8.6.8.1. Key country dynamics
8.6.8.2. Regulatory framework/ reimbursement structure
8.6.8.3. Competitive scenario
8.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.7. Asia Pacific
8.7.1. Japan
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/ reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.7.2. China
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.7.3. India
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/ reimbursement structure
8.7.3.3. Competitive scenario
8.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.7.4. Australia
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/ reimbursement structure
8.7.4.3. Competitive scenario
8.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.7.5. South Korea
8.7.5.1. Key country dynamics
8.7.5.2. Regulatory framework/ reimbursement structure
8.7.5.3. Competitive scenario
8.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.7.6. Thailand
8.7.6.1. Key country dynamics
8.7.6.2. Regulatory framework/ reimbursement structure
8.7.6.3. Competitive scenario
8.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.8. Latin America
8.8.1. Brazil
8.8.1.1. Key country dynamics
8.8.1.2. Regulatory framework/ reimbursement structure
8.8.1.3. Competitive scenario
8.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.8.2. Mexico
8.8.2.1. Key country dynamics
8.8.2.2. Regulatory framework/ reimbursement structure
8.8.2.3. Competitive scenario
8.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.8.3. Argentina
8.8.3.1. Key country dynamics
8.8.3.2. Regulatory framework/ reimbursement structure
8.8.3.3. Competitive scenario
8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.9. MEA
8.9.1. South Africa
8.9.1.1. Key country dynamics
8.9.1.2. Regulatory framework/ reimbursement structure
8.9.1.3. Competitive scenario
8.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.9.2. Saudi Arabia
8.9.2.1. Key country dynamics
8.9.2.2. Regulatory framework/ reimbursement structure
8.9.2.3. Competitive scenario
8.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.9.3. UAE
8.9.3.1. Key country dynamics
8.9.3.2. Regulatory framework/ reimbursement structure
8.9.3.3. Competitive scenario
8.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
8.9.4. Kuwait
8.9.4.1. Key country dynamics
8.9.4.2. Regulatory framework/ reimbursement structure
8.9.4.3. Competitive scenario
8.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million) (Number of Patients Treated in Thousands)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Vendor Landscape
9.3.1. List of key distributors and channel partners
9.3.2. Key customers
9.3.3. Key company market share analysis, 2023
9.3.4. Johnson & Johnson Services, Inc.
9.3.4.1. Company overview
9.3.4.2. Financial performance
9.3.4.3. Product benchmarking
9.3.4.4. Strategic initiatives
9.3.5. Cipla, Inc.
9.3.5.1. Company overview
9.3.5.2. Financial performance
9.3.5.3. Product benchmarking
9.3.5.4. Strategic initiatives
9.3.6. Sun Pharmaceutical Industries Ltd.
9.3.6.1. Company overview
9.3.6.2. Financial performance
9.3.6.3. Product benchmarking
9.3.6.4. Strategic initiatives
9.3.7. Merck & Co., Inc.
9.3.7.1. Company overview
9.3.7.2. Financial performance
9.3.7.3. Product benchmarking
9.3.7.4. Strategic initiatives
9.3.8. Dr. Reddy’s Laboratories Ltd.
9.3.8.1. Company overview
9.3.8.2. Financial performance
9.3.8.3. Product benchmarking
9.3.8.4. Strategic initiatives
9.3.9. Aurobindo Pharma
9.3.9.1. Company overview
9.3.9.2. Financial performance
9.3.9.3. Product benchmarking
9.3.9.4. Strategic initiatives
9.3.10. Lexington Intl., LLC
9.3.10.1. Company overview
9.3.10.2. Financial performance
9.3.10.3. Product benchmarking
9.3.10.4. Strategic initiatives
9.3.11. Freedom Laser Therapy, Inc. (iRESTORE Hair Growth System)
9.3.11.1. Company overview
9.3.11.2. Financial performance
9.3.11.3. Product benchmarking
9.3.11.4. Strategic initiatives
9.3.12. Curallux, LLC
9.3.12.1. Company overview
9.3.12.2. Financial performance
9.3.12.3. Product benchmarking
9.3.12.4. Strategic initiatives
9.3.13. Apira Science, Inc. (iGROW Laser)
9.3.13.1. Company overview
9.3.13.2. Financial performance
9.3.13.3. Product benchmarking
9.3.13.4. Strategic initiatives
9.3.14. Theradome, Inc.
9.3.14.1. Company overview
9.3.14.2. Financial performance
9.3.14.3. Product benchmarking
9.3.14.4. Strategic initiatives